BACKGROUND The BRAFV600E mutation is the most common diagnostic/prognostic
marker in papillary thyroid carcinoma (PTC). Its evaluation is typically performed with DNA …

BRAF V600E is a common mutation in papillary thyroid carcinoma (PTC) correlated with
aggressive features. Our objective was to assess the feasibility and accuracy of a novel RNA …

Patients with differentiated thyroid cancer usually present with early-stage disease and
undergo surgery followed by adjuvant radioactive iodine ablation, resulting in excellent …

Abstract Background The BRAFV600E mutation status is a useful diagnostic and prognostic
marker for papillary thyroid carcinoma (PTC). Although it is a commonly used method …

BACKGROUND: Approximately 30% of fine needle aspiration biopsies of the thyroid have
inconclusive results. We conducted a prospective trial to determine whether clinical and …

Background BRAF V600E mutation has been reported to show a high specificity for papillary
thyroid carcinoma (PTC). Using this marker to upgrade 'indeterminate'or 'suspicious' thyroid …

Background: The current preoperative diagnosis of a thyroid mass relies on microscopic
evaluation of thyroid cells obtained by fine needle aspiration biopsy (FNAB). More recently …

In an increased number of settings, cytology represents the only source of sampling and it
often substitutes histology as an independent diagnostic modality. Thus, DNA molecular …

Objective: The BRAF V600E mutation has been associated with aggressive disease in
papillary thyroid carcinoma (PTC). Molecular testing has been proposed as a useful adjunct …

Background: BRAFV600E is the most common mutation in papillary thyroid carcinoma (PTC)
and can be associated with aggressive disease. Previously, a highly sensitive blood RNA …